Foreign or Domestic CARs: Receptor Ligands as Antigen-Binding Domains
Chimeric antigen receptors (CARs) are increasingly being used in clinical trials to treat a variety of malignant conditions and recent results with CD19-specific CARs showing complete tumor regressions has sparked the interest of researchers and the public alike. Traditional CARs have been generated...
Main Authors: | Donald R. Shaffer, Penghui Zhou, Stephen Gottschalk |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-01-01
|
Series: | Medical Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-3271/2/1/23 |
Similar Items
-
Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell
by: Leila Jafarzadeh, et al.
Published: (2020-06-01) -
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
by: Mohamed-Reda Benmebarek, et al.
Published: (2019-03-01) -
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
by: Dongfang Liu, et al.
Published: (2020-08-01) -
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
by: Astero Klampatsa, et al.
Published: (2017-09-01) -
Novel antigens of CAR T cell therapy: New roads; old destination
by: Pooria Safarzadeh Kozani, et al.
Published: (2021-07-01)